Impact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 study.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: mRCC treated with nivolumab
I · Intervention 중재 / 시술
nivolumab, categorizing them into BTA and non-BTA groups
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] This study suggests a potential beneficial impact of BTAs, especially denosumab, on the clinical outcomes after nivolumab therapy in mRCC patients with bone metastases. Prospective trials are needed to better define the impact of BTAs in these patients.
[BACKGROUND] Immune checkpoint inhibitors have revolutionized the treatment landscape for metastatic renal cell carcinoma (mRCC).
- HR 0.57
APA
Pantano F, Malgeri A, et al. (2026). Impact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 study.. Frontiers in oncology, 16, 1754327. https://doi.org/10.3389/fonc.2026.1754327
MLA
Pantano F, et al.. "Impact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 study.." Frontiers in oncology, vol. 16, 2026, pp. 1754327.
PMID
41788982 ↗
Abstract 한글 요약
[BACKGROUND] Immune checkpoint inhibitors have revolutionized the treatment landscape for metastatic renal cell carcinoma (mRCC). However, some patients fail to experience durable benefits, especially those with bone metastases.
[OBJECTIVE] This study aimed to evaluate the impact of bone-targeting agents (BTAs), specifically denosumab and zoledronic acid (ZA), on the clinical outcomes of patients with mRCC treated with nivolumab.
[METHODS] This retrospective study analyzed data from the Meet-URO 15 trial on patients with mRCC who received nivolumab, categorizing them into BTA and non-BTA groups. Survival outcomes were assessed, with inverse probability of treatment weighting (IPTW) adjustment for confounding variables. Subsequently, the specific impact of different BTAs on the clinical outcomes was explored.
[RESULTS] Of 203 mRCC patients with bone metastases, 38 received BTAs (BTA group) while 138 did not (non-BTA group). BTA treatment significantly improved the median progression-free survival (PFS) (291 . 117 days, = 0.005) and overall survival (OS) (960 . 397 days, = 0.008) compared with the non-BTA group, with a reduced risk of death (HR = 0.57, 95%CI = 0.34-0.95, = 0.031) and progression or death (HR = 0.57, 95%CI = 0.35-0.92, = 0.023) at multivariate analyses. IPTW adjustment confirmed these survival benefits, with a reduced risk of death (HR = 0.55-95%CI = 0.39-0.76, < 0.001) and progression or death (HR = 0.58, 95%CI = 0.42-0.79, < 0.001) in BTA patients. Furthermore, denosumab, compared with ZA and the non-BTA group, demonstrated superior OS (1,662 . 681 . 411 days, < 0.001) and PFS (1,101 . 242 . 132 days, < 0.001) in the same IPTW-adjusted population.
[CONCLUSION] This study suggests a potential beneficial impact of BTAs, especially denosumab, on the clinical outcomes after nivolumab therapy in mRCC patients with bone metastases. Prospective trials are needed to better define the impact of BTAs in these patients.
[OBJECTIVE] This study aimed to evaluate the impact of bone-targeting agents (BTAs), specifically denosumab and zoledronic acid (ZA), on the clinical outcomes of patients with mRCC treated with nivolumab.
[METHODS] This retrospective study analyzed data from the Meet-URO 15 trial on patients with mRCC who received nivolumab, categorizing them into BTA and non-BTA groups. Survival outcomes were assessed, with inverse probability of treatment weighting (IPTW) adjustment for confounding variables. Subsequently, the specific impact of different BTAs on the clinical outcomes was explored.
[RESULTS] Of 203 mRCC patients with bone metastases, 38 received BTAs (BTA group) while 138 did not (non-BTA group). BTA treatment significantly improved the median progression-free survival (PFS) (291 . 117 days, = 0.005) and overall survival (OS) (960 . 397 days, = 0.008) compared with the non-BTA group, with a reduced risk of death (HR = 0.57, 95%CI = 0.34-0.95, = 0.031) and progression or death (HR = 0.57, 95%CI = 0.35-0.92, = 0.023) at multivariate analyses. IPTW adjustment confirmed these survival benefits, with a reduced risk of death (HR = 0.55-95%CI = 0.39-0.76, < 0.001) and progression or death (HR = 0.58, 95%CI = 0.42-0.79, < 0.001) in BTA patients. Furthermore, denosumab, compared with ZA and the non-BTA group, demonstrated superior OS (1,662 . 681 . 411 days, < 0.001) and PFS (1,101 . 242 . 132 days, < 0.001) in the same IPTW-adjusted population.
[CONCLUSION] This study suggests a potential beneficial impact of BTAs, especially denosumab, on the clinical outcomes after nivolumab therapy in mRCC patients with bone metastases. Prospective trials are needed to better define the impact of BTAs in these patients.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Atypical femoral fracture with early PET/CT changes from denosumab for metastatic breast cancer and transition from denosumab to zoledronic acid.
- Denosumab Plus Immune Checkpoint Inhibitors in Bone Metastases From Solid Tumors.
- Clinical Features Associated With Outcomes in Lung Cancer Patients Treated With Denosumab.
- Longitudinal monitoring of denosumab-associated bone changes by REMS in postmenopausal women with ER-positive breast cancer receiving aromatase inhibitors.
- Denosumab Combined With PARP Inhibitors and Chemoradiotherapy for Treating Triple Negative Breast Cancer With Bone Metastasis: A Case Report.
- Which monoclonal antibodies cause osteonecrosis of the jaws? An overview of the current literature excluding denosumab.